KIMBERLY ATWOOD: Open Payments
NPI 1700161593 · DURHAM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$569 in 27 payments from 13 companies in 2025. Trend: 2023 $439 · 2024 $663 · 2025 $569
Food & beverage: $569
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $112 |
| Calliditas Therapeutics US Inc. | 3 | $81 |
| Travere Therapeutics, Inc. | 5 | $73 |
| GlaxoSmithKline, LLC. | 2 | $47 |
| Fresenius USA Marketing, Inc. | 2 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $43 |
| Cycle Pharmaceuticals Inc | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Ardelyx, Inc. | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $23 |
Products named: TARPEYO, BENLYSTA, VELPHORO, Kerendia, Vanrafia, Venxxiva, JYNARQUE, IBSRELA.
Industry payments across NC — which companies pay providers there.
